Enavate Sciences GP LLC Sells 1,154,784 Shares of Immunome, Inc. $IMNM

Enavate Sciences GP LLC lessened its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 24.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,613,799 shares of the company’s stock after selling 1,154,784 shares during the quarter. Immunome makes up approximately 22.5% of Enavate Sciences GP LLC’s holdings, making the stock its 2nd largest holding. Enavate Sciences GP LLC’s holdings in Immunome were worth $79,034,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in IMNM. T. Rowe Price Investment Management Inc. lifted its holdings in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares during the last quarter. Primecap Management Co. CA grew its holdings in shares of Immunome by 55.2% during the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares in the last quarter. State Street Corp grew its holdings in shares of Immunome by 37.9% during the fourth quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after buying an additional 1,064,027 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after buying an additional 2,823,144 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Trading Up 1.7%

Shares of Immunome stock opened at $22.58 on Tuesday. Immunome, Inc. has a twelve month low of $8.66 and a twelve month high of $27.65. The stock has a market capitalization of $2.56 billion, a P/E ratio of -9.49 and a beta of 2.07. The business’s fifty day moving average price is $21.08 and its 200 day moving average price is $21.98.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, sell-side analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research note on Friday, July 17th. Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Wedbush reissued an “outperform” rating and set a $31.00 price target on shares of Immunome in a research note on Tuesday, July 21st. Finally, Truist Financial raised their price objective on Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Thirteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $33.17.

Insider Buying and Selling at Immunome

In other Immunome news, Director Jean Jacques Bienaime bought 10,500 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was purchased at an average price of $19.45 per share, with a total value of $204,225.00. Following the transaction, the director owned 43,415 shares in the company, valued at $844,421.75. This trade represents a 31.90% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Isaac Barchas sold 16,906 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20. Following the completion of the transaction, the director owned 108,504 shares in the company, valued at $2,625,796.80. The trade was a 13.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 472,142 shares of company stock worth $10,262,648. Company insiders own 7.21% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.